Researchers at Sweden's Karolinska Institutet and the University of Oulu in Finland have elucidated gene regulatory mechanisms that can explain how known genetic variants influence prostate cancer risk. The findings, published ...
Mar 7, 2016
0
24
When we think about sex hormones, notably estrogens and androgens, we usually associate them with sex, gender and body development. Like all hormones, they are chemical messengers, substances produced in one part of the body ...
Feb 23, 2016
0
1
The 3 million prostate cancer survivors in the United States are likely to die from something other than cancer, thanks to early detection, effective treatment and the disease's slow progression.
Feb 10, 2016
0
5
Debiopharm International SA (Debiopharm), part of Debiopharm Group, a Swiss-based global biopharmaceutical company, today announced a collaboration in order to supply triptorelin pamoate 3.75 mg 1-month formulation for patients ...
Jan 14, 2016
0
0
A newly discovered connection between two common prostate cancer treatments may soon make prostate cancer cells easier to destroy. Drugs that could capitalize on the discovery are already in the pipeline, and a clinical trial ...
Dec 18, 2015
1
31
Globally, prostate cancer is the second most common type of cancer and the fifth leading cause of cancer-related death in men.
Dec 9, 2015
0
2
(HealthDay)—Hormone therapy for prostate cancer might dramatically increase a man's risk of developing Alzheimer's disease, a large-scale analysis of health data suggests.
Dec 8, 2015
0
59
Results of a multicenter phase 1 clinical trial presented today at the 2015 San Antonio Breast Cancer Symposium show that the anti-androgen agent enzalutamide is active and well-tolerated alone and with fulvestrant in patients ...
Dec 7, 2015
0
0
Scientists have gained a key insight into how prostate tumors get their start - not by rewriting the normal DNA code, but by reprogramming the master regulator of genes in prostate cells to drive malignant growth.
Oct 12, 2015
0
103
Long term follow up indicates that men with comorbidity, predominately a prior heart attack, who received androgen deprivation therapy (ADT) died earlier, due to a fatal heart attack.
Sep 22, 2015
0
8
